Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa
We present our experience with combined biologic and surgical therapy for recalcitrant HS. Methods: Between 2011 and 2014, 21 patients (57 cases) with Hurley Stage III HS underwent radical resection with delayed primary closure alone, or in combination with adjuvant biologic therapy. Demographic data, treatment regimen, outcomes, and complications were retrospectively reviewed for all cases. Results: Eleven patients underwent combined surgical and biologic therapy, whereas radical resection alone was performed in 10 patients. The average soft tissue deficit, before closure, for the combined and surgery-only patients was 56 cm2 and 48.5 cm2, respectively (P = 0.66). Biologic agents including infliximab (n = 8) and ustekinumab (n = 3) were initiated 2 to 3 weeks after closure and were continued for an average of 10.5 months. Recurrence was noted in 19% (4/29) and 38.5% (10/26) of previously treated sites for combined and surgery-only patients (P
Condition: Acne Inversa Interventions: Drug: PF-06650833; Drug: PF-06700841; Drug: PF-06826647; Drug: Placebo Sponsor: Pfizer Not yet recruiting
Hidradenitis Suppurativa (HS) is a prevalent and debilitating inflammatory skin disease characterized by painful and recurrent nodules and abscesses, malodorous purulent drainage, and disfiguring sinus tract and scar formation involving intertriginous body sites. Microorganisms have been implicated in HS pathogenesis, and broad-spectrum antimicrobial therapy is one of the mainstays of HS management. However, bacteria have been identified in only ∼50% of HS lesions using conventional culture-based methods and no consistent organism has been cultured from HS lesions.(Brook and Frazier, 1999, Gener et al., 2009, Jemec, 20...
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that is estimated to affect up to 4% of the population. Patients with HS are at increased risk for anxiety, depression, and suicide. Despite the prevalence of this disease, there is still underrecognition and often a delay in diagnosis. For successful treatment, a multimodal approach is recommended. Effective treatments include excision surgery, tumor necrosis factor (TNF) inhibitor therapy, antibiotics, hormonal therapy, and metformin.
WEDNESDAY, Sept. 11, 2019 -- Patients with hidradenitis suppurativa (HS) have an increased risk for long-term opioid use, according to a study published online Sept. 11 in JAMA Dermatology. Sarah Reddy, from the Zucker School of Medicine at...
This cohort study compares overall and subgroup incidence of long-term opioid use in a population of opioid-naive patients with hidradenitis suppurativa and controls from US electronic health record data.
Condition: Hidradenitis Suppurativa Intervention: Drug: Guselkumab Sponsors: Rockefeller University; Janssen Scientific Affairs, LLC Not yet recruiting
Contributors : Christos C Zouboulis ; Andre Nogueira da Costa ; Eugenia Makrantonaki ; Xiao X Hou ; Daifallah Almansouri ; Joel T Dudley ; Hannah Edwards ; Ben Readhead ; Ottfried Balthasar ; G B Jemec ; Nikolaos G Bonitsis ; Georgios Nikolakis ; Dietrich Trebing ; Konstantin C Zouboulis ; Amir M HossiniSeries Type : Expression profiling by arrayOrganism : Homo sapiensHidradenitis Suppurativa molecular taxonomy and key signaling pathways were studied by whole transcriptome profiling. Dysregulated genes were detected by comparing lesional and non lesional skin obtained from female HS patients and matched healthy controls us...
This article is protected by copyright. All rights reserved. PMID: 31494929 [PubMed - as supplied by publisher]
PMID: 31494923 [PubMed - as supplied by publisher]
This article provides an overview of the principles in the evaluation and management of perianal Crohn's disease (CD). Manifestation-specific treatment is addressed including abscess, fistula, skin tags, hemorrhoids, fissure, ulcers, strictures, ano-, and rectovaginal fistulas as well CD-associated hidradenitis suppurativa. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Abstract | Full text